X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
October 26, 2022 at 08:00 am EDT
Share
X4 Pharmaceuticals, Inc. announced the appointment of Mark Baldry to the position of Chief Commercial Officer. In this key role, Mr. Baldry will lead all
pre-commercial and product launch efforts for the company's lead therapeutic candidate, mavorixafor, a small molecule being developed as a once-daily oral therapy for chronic neutropenic disorders, including WHIM syndrome. Mr. Baldry's previous roles include Chief Commercial Officer of Freeline Therapeutics Holdings, Chief Commercial Officer of Wave Life Sciences, and Vice President, Global Marketing and then Senior Vice President, Global Marketing & Commercial Operations at Amicus Therapeutics. In these roles, he was responsible for building and executing on global commercial strategies to support successful launches of innovative medicines in orphan diseases, including the first oral chaperone therapy for the treatment of Fabry disease. Throughout his earlier career, Mr. Baldry held multiple leadership positions at Biogen Inc., including Vice President, Public Affairs and Vice President, New Product Commercialization, and at the Human Genetic Therapies division of Shire Pharmaceuticals, where he served as Head of Global Strategic Marketing and Head of Marketing, Market Access and Public Affairs, Europe, Middle East, and Africa. Mr. Baldry received a BSc in Genetics from York University (U.K.) and an MBA from Concordia University (Canada). About X4 PharmaceuticalsX4 Pharmaceuticals is a late stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.